First and second generation antipsychotics and morphological and neurochemical brain changes in schizophrenia. Review of magnetic resonance imaging and proton spectroscopy findings;Leki antypsychotyczne pierwszej i drugiej generacji a zmiany morfologiczne i neurochemiczne w mózgu w schizofrenii. Przegla̧d wyników badań rezonansu magnetycznego i spektroskopii protonowej

Psychiatria Polska

Volumn 41, Issue 3, 2007, Pages 329-338

  Szulc, Agata ^a,b  

^a Klinika Psychiatrii AM W Bia ymstoku

^b Klinika Psychiatrii AM   (Poland)

Author keywords

Antipsychotics; Magnetic resonance imaging; Proton spectroscopy; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT;

BRAIN NERVE CELL; BRAIN REGION; BRAIN TISSUE; CELL VIABILITY; DRUG ACTIVITY; DRUG MECHANISM; HUMAN; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SCHIZOPHRENIA; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; ASPARTIC ACID; BASAL GANGLIA; BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PROTONS; SCHIZOPHRENIA;

EID: 34447534557     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr. Res. 2001; 49: 1-52.
2. Szulc A, Galińska B, Czernikiewicz A. Schizofrenia - bliżej do koncepcji neurorozwojowej czy neurodegeneracyjnej? Psychiatr. Pol. 2005; 39: 249-258.
3. Keshavan MS, Berger G, Zipursky RB, Wood SJ, Pantelis C. Neurobiology of early psychosis. Brit. J. Psychiatry 2005; 187, supl. 43: 8-18.
4. Bustillo J, Wolff C, Gutierrez AM, Dettmer TS, Cooper TB, Allan A, Lauriello J, Velenzuela CF. Treatments of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels. Schizophr. Res. 2004; 66: 31-39.
5. van Elst T, Baumer D, Ebert D, Trimble MR. Chronic antidopaminergic medication might affect amygdala structure in patients with schizophrenia. Pharmacopsychiatry 2004; 37: 217-220.
6. Lang DJ, Kopala LC, Vandorpe RA, Rui C. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Am. J. Psychiatry 2004; 161: 1829-1837.
7. Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC. Change in basal ganglia volume over 2 years in patients with schizophrenia: Typical versus atypical neuroleptics. Am. J. Psychiatry 1999; 156: 1200-1204.
8. Lang DJ, Kopala LC, Vandorpe RA, Goghari VM, Honer WG. An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidonr. Am. J. Psychiatry 2001; 158: 625-631.
9. Liebermann JA, Tollefson GD, Charles C, Zipursky R. Antipsychotic drug effect on brain morphology in first episode schizophrenia. Arch. Gen. Psychiatry 2005; 62: 361-370.
10. Andersson C, Hamer RM, Lawler CP, Mailman RB, Lieberman JA. Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. Neuropsychopharmacol. 2002; 27: 143-151.
11. Arrango C, Breier A, McMahon, Carpenter WT, Buchanan RW. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am. J. Psychiatry 2003; 160: 1421-1427.
12. Kopelman A, Andreasen NC, Nopulos P. Morphology of the anterior cingulate gyrus in patients with schizophrenia: Relationship to typical neuroleptic exposure. Am. J. Psychiatry 2005; 162: 1872-1878.
13. Molina V, Reig S, Sanz J, Palomo T, Benito C, Sanchez J, Sarramea F, Pascau J, Desco M. Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophr. Res. 2005; 80: 61-71.
14. Garver DL, Holcomb J A, Christensen JD. Cerebral cortical gray expansion associated with two second generation antipsychotics. Biol. Psychiatry 2005; 58: 62-66.
15. Chakos MH, Schobel SA, Gu H, Gerig G, Bradford D, Charles C, Lieberman JA. Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. Brit. J. Psychiatry 2005; 186: 26-31.
16. Schmitt A, Weber S, Jatzko A, Braus DF, Henn FA. Hippocampal volume and cell proliferation after acute and chronic clozapine or haloperodol treatment. J. Neural Transm. 2004; 111: 91-100.
17. Harte MK, Bachus SB, Reynolds GP. Increased N-acetylaspartate in rat striatum following long term administration of haloperidol. Schizophr. Res. 2005; 75: 303-308.
18. Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol. Psychiatry 2001; 50: 729-742.
19. Ende G, Braus DF, Walter S, Weber-Fahr W, Soher B, Maudsley AA, Henn FA. Effects of age, medication, and illness duration on the N-acetylaspartate signal of the anterior cingulate region in schizophrenia. Schizophr. Res. 2000; 41: 389-395.
20. Szulc A, Galińska B. Postȩpy w neuroobrazowaniu zaburzeń psychicznych. Spektroskopia rezonansu magnetycznego (MRS). Psychiatr. Dypl. 2004.
21. Szulc A, Galińska B, Tarasów E, Dzienis W, Kubas B, Konarzewska B, Walecki J, Czernikiewicz A. The effect of risperidone on metabolite measures in the frontal lobe, temporal lobe, and thalamus in schizophrenia. A proton magnetic resonance spectroscopy (1H MRS) study. Pharmacopsychiatry 2005; 38: 214-219.
22. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF, Weinberger DR. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol. Psychiatry 2001; 49: 39-46.
23. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest. Radiol. 1996; 31: 345-352.
24. Heimberg C, Komoroski RA, Lawson WB, Cardwell D, Karson CN. Regional magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiatry Res. 1998; 83: 105-115.
25. Braus DF, Ende G, Weber-Fahr W, Demiracka T, Henn FA. Favorable effect on neuronal viability in the anterior cingulated gyrus due to long-term treatment with atypical antipsychotics: an MRSI study. Pharmacopsychiatry 2001; 34: 251-253.
26. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol. Psychiatry 2002; 51: 493-497.
27. Lindquist DM, Hawk RM, Karson CN, Komoroski RA. Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. Magn. Res. Med. 2000; 43: 355-358.
28. Fannon D, Simmons A, Tennakoon L, O'Ceallaigh, Sumich A, Doku V, Shew C, Sharma T. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biol. Psychiatry 2003; 54: 587-598.
29. Pae CU, Choe BY, Joo RH, Lim HK, Kim TS, Yoo SS, Choi BG, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU. Neuronal dysfunction of the frontal lobe in schizophrenia. Neuropsychobiol. 2004; 50: 211-215.
30. Bustillo JR, Lauriello J, Rowland LM, Jung RE, Petropoulos H, Hart BL, Blanchard J, Keith SJ, Brooks WM. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Res. 2001; 107: 135-149.
31. Bustillo JR, Lauriello J, Rowland LM, Thomson LM, Petropoulos H, Hammond R, Hart B, Brooks WM. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr. Res. 2002; 58: 313-321.